EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Otitis Media - Pipeline Review, H1 2017

  • ID: 4091150
  • Report
  • February 2017
  • 82 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cellceutix Corp
  • ContraFect Corp
  • GlaxoSmithKline Plc
  • Madam Therapeutics BV
  • Merck & Co Inc
  • Otonomy Inc
  • MORE
Otitis Media - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2017, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cellceutix Corp
  • ContraFect Corp
  • GlaxoSmithKline Plc
  • Madam Therapeutics BV
  • Merck & Co Inc
  • Otonomy Inc
  • MORE
Introduction

Otitis Media - Overview

Otitis Media - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media - Companies Involved in Therapeutics Development

Cellceutix Corp

ContraFect Corp

GlaxoSmithKline Plc

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Otonomy Inc

Yuhan Corp

Otitis Media - Drug Profiles

(cholesteryl palmitate + colfosceril palmitate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betahistine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-309 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ciprofloxacin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ciprofloxacin hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2189242A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1440 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (23-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Otitis Media - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Otitis Media - Dormant Projects

Otitis Media - Product Development Milestones

Featured News & Press Releases

Nov 02, 2016: Otonomy Announces Assignment of J Code for OTIPRIO

Oct 07, 2016: Otonomy Holds Investor and Analyst Day and Provides Corporate Update

Oct 04, 2016: Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes

Sep 15, 2016: Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO in Patients with History of Otitis Media Requiring Tympanostomy Tubes

May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO

May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings

Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology

Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO

Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery

Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes

Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting

May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application

Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Otitis Media, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Otitis Media - Pipeline by Cellceutix Corp, H1

Otitis Media - Pipeline by ContraFect Corp, H1

Otitis Media - Pipeline by GlaxoSmithKline Plc, H1

Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1

Otitis Media - Pipeline by Madam Therapeutics BV, H1

Otitis Media - Pipeline by Merck & Co Inc, H1

Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1

Otitis Media - Pipeline by Otonomy Inc, H1

Otitis Media - Pipeline by Yuhan Corp, H1

Otitis Media - Dormant Projects, H1

List of Figures:

Number of Products under Development for Otitis Media, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Cellceutix Corp
  • ContraFect Corp
  • GlaxoSmithKline Plc
  • Lee's Pharmaceutical Holdings Ltd
  • Madam Therapeutics BV
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • Otonomy Inc
  • Yuhan Corp
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll